Abstract |
Primary percutaneous coronary intervention (PPCI) is superior to thrombolysis in STEMI ( ST segment elevation myocardial infarction) patients. Data on late stent thrombosis (ST) have raised concerns regarding the use of drug-eluting stents during PPCI. We report the first 3-year clinical evaluation of the zotarolimus-eluting stent (ZES) in patients undergoing PPCI for STEMI, a single-center, prospective cohort study of consecutive patients admitted with STEMI. All underwent PPCI within 12 hours of symptoms; each received one or more ZES in one or more target lesions. All patients received aspirin 300 mg, clopidogrel 600 mg, abciximab, and unfractionated heparin. A total of 102 STEMI patients (76 male, mean 62 years) received 162 ZES (mean 1.6 stents/patient). Median call-to-balloon time was 123 (102-152) minutes. Thirty-day combined major adverse cardiovascular event ( MACE) rate was 3.9% (n = 4). Subacute ST occurred in 2 patients (1.96%). Combined MACE rates at 12 months and 3 years were 7.8% (n = 8) and 13.7% (n = 14). Late ST occurred in 1 patient (1%) with no occurrence of very late ST. This is the first 3-year report of the use of the ZES in an unselected, consecutive PPCI population. Overall 3-year incidence of MACE and target lesion revascularization (5.9%) was low, and was comparable to that seen with sirolimus- and paclitaxel-eluting stents in randomized controlled trials. At 3 years there was no occurrence of very late ST.
|
Authors | Rhidian J Shelton, Kamal Chitkara, Ravi Singh, Micha F Dorsch, Kathryn Somers, James M McLenachan, Jonathan M Blaxill, Stephen B Wheatcroft, Daniel J Blackman, John P Greenwood |
Journal | Journal of interventional cardiology
(J Interv Cardiol)
Vol. 24
Issue 6
Pg. 542-8
(Dec 2011)
ISSN: 1540-8183 [Electronic] United States |
PMID | 21883474
(Publication Type: Journal Article)
|
Copyright | ©2011, Wiley Periodicals, Inc. |
Chemical References |
- Anticoagulants
- Immunosuppressive Agents
- Platelet Aggregation Inhibitors
- Heparin
- Clopidogrel
- zotarolimus
- Ticlopidine
- Aspirin
- Sirolimus
|
Topics |
- Angioplasty, Balloon, Coronary
(adverse effects, statistics & numerical data)
- Anticoagulants
(therapeutic use)
- Aspirin
(therapeutic use)
- Clopidogrel
- Confidence Intervals
- Drug-Eluting Stents
(adverse effects)
- Female
- Heparin
(therapeutic use)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy, mortality, therapy)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Prospective Studies
- Sirolimus
(administration & dosage, analogs & derivatives, therapeutic use)
- Ticlopidine
(analogs & derivatives, therapeutic use)
- Time Factors
- Treatment Outcome
- United Kingdom
|